Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of April 1, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
舊金山，2024年4月2日（環球新聞專線）——專注於女性癌症靶向療法發現、開發和商業化的臨床階段生物製藥公司奧萊瑪製藥公司（“Olema” 或 “Olema Oncology”，納斯達克股票代碼：OLMA）今天宣佈，該公司向兩名新員工授予股票期權，以購買公司總共6萬股普通股，自 2024 年 4 月 1 日起生效。根據納斯達克上市規則5635（c）（4），這些獎勵已獲得奧萊瑪董事會薪酬委員會的批准，並根據公司的2022年激勵計劃發放，發放日期爲2024年4月1日，作爲激勵新員工在奧萊瑪工作的激勵材料。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $10.89 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on April 1, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
股票期權在四年內歸屬，25％的股票期權在歸屬開始日期一週年之際歸屬，其餘部分在接下來的三年中按月等額分期歸屬，前提是該員工在該歸屬之日繼續受僱於Olema。股票期權的期限爲10年，行使價爲每股10.89美元，等於納斯達克於2024年4月1日公佈的公司普通股最新公佈的銷售價格。股票期權受奧萊瑪製藥公司2022年激勵計劃的條款約束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
奧萊瑪根據納斯達克上市規則5635（c）（4）提供這些信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
關於 Olema Oncol
Olema Oncology是一家處於臨床階段的生物製藥公司，致力於改變癌症女性的護理標準並改善其療效。Olema利用我們對內分泌驅動的癌症、核受體和獲得性耐藥機制的深刻理解，正在推進一系列新療法。除了我們的主要候選產品palazestrant（OP-1250）（一種專有的口服完全雌激素受體（ER）拮抗劑（CERAN）和選擇性ER降解劑（SERD）外，Olema還在開發一種有效的KAT6抑制劑（OP-3136）。Olema 總部位於舊金山，在馬薩諸塞州劍橋開展業務。欲了解更多信息，請訪問我們。
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com
聯繫我們:
Geoffrey Mogilner，投資者關係與傳播副總裁
ir@olema.com
譯文內容由第三人軟體翻譯。